BioCardia logo
BioCardia BCDA
$ 1.16 0.0%

Annual report 2025
added 03-24-2026

report update icon

BioCardia Balance Sheet 2011-2026 | BCDA

Annual Balance Sheet BioCardia

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-1.97 M -1.42 M 212 K -5.73 M -11 M -20.8 M -4.44 M -5.36 M -12.7 M -21.4 M -13.8 M -13.5 M -13.3 M -13.3 M -12.7 M

Long Term Debt

86 K 566 K 982 K 1.32 M 1.63 M - - - - - - - - - -

Long Term Debt Current

442 K 385 K 333 K 315 K 237 K 614 K 528 K - - - - - - - -

Total Non Current Liabilities

- - - - - - 1.3 M 77 K 81 K 56 K - - - - -

Total Current Liabilities

2.43 M 2.32 M 3.61 M 3.58 M 3.71 M 4.25 M 4 M 2.55 M 2.33 M 1.44 M - - - - -

Total Liabilities

2.52 M 2.89 M 4.59 M 4.9 M 5.34 M 4.25 M 5.31 M 2.62 M 2.41 M 1.5 M 10 K 1 K 18 K 12 K 756 K

Deferred Revenue

- - - 341 K 847 K 683 K 102 K 112 K 228 K 137 K - - - - -

Retained Earnings

-168 M -160 M -152 M -141 M -129 M - -101 M -86.4 M -72.4 M -60.1 M -12.1 M -12.5 M -12.7 M -12.7 M -13 M

Total Assets

3.41 M 3.72 M 2.99 M 9.79 M 15.7 M 23.4 M 7.68 M 6.42 M 13.5 M 22.1 M 13.9 M 13.5 M 13.3 M 13.3 M 13.7 M

Cash and Cash Equivalents

2.5 M 2.37 M 1.1 M 7.36 M 12.9 M 21.4 M 5.58 M 5.36 M 12.7 M 21.4 M 3.56 M 3.18 M 13.3 M 13.3 M 12.7 M

Book Value

895 K 837 K -1.6 M 4.89 M 10.4 M 19.2 M 2.37 M 3.79 M 11.1 M 20.6 M 13.9 M 13.5 M 13.3 M 13.3 M 13 M

Total Shareholders Equity

895 K 837 K -1.6 M 4.89 M 10.4 M 19.2 M 2.37 M 3.79 M 11.1 M 20.6 M -3.44 M -43.1 K 13.5 M 13.3 M 13 M

All numbers in USD currency

Quarterly Balance Sheet BioCardia

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

211 K 333 K 452 K 566 K 674 K 780 K 883 K 982 K 1.08 M 1.14 M 1.23 M 1.32 M 1.4 M 1.48 M 1.56 M 1.63 M - - - - 161 K 316 K 468 K 614 K 614 K 614 K 614 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

3.52 M 3.98 M 3.69 M 2.89 M 3.51 M 4.85 M 4.95 M 4.59 M 4.41 M 4.75 M 5.23 M 4.9 M 5.08 M 4.53 M 5.47 M 5.34 M 3.92 M 4.54 M 4.75 M 4.25 M 4.25 M 4.25 M 4.25 M 5.31 M 5.31 M 5.31 M 5.31 M 2.62 M 2.62 M 2.62 M 2.62 M 2.41 M 2.41 M 2.41 M 2.41 M 1.5 M 1.5 M 1.5 M 1.5 M 8.3 M 10 K 10 K 10 K 10 K 1 K 1 K - 1 K 5 K 1 K 1 K 12 K 12 K 12 K 12 K 756 K 756 K 756 K 756 K

Deferred Revenue

- - - - - - - - - 333 K 340 K 341 K 378 K - 948 K 847 K 886 K 1.42 M 1.18 M 683 K 683 K 683 K 683 K 102 K 252 K 102 K 102 K 112 K 112 K 112 K 60 K 167 K 167 K 167 K 167 K 71 K 71 K 71 K 71 K 39 K - - - - - - - - - - - - - - - - - - -

Retained Earnings

-166 M -165 M -163 M -160 M -158 M -156 M -154 M -152 M -150 M -148 M -144 M -141 M -138 M -135 M 138 M -129 M -125 M -123 M -119 M -116 M -116 M -116 M -116 M -101 M -101 M -101 M -101 M -86.4 M -86.4 M -86.4 M -86.4 M -72.4 M -72.4 M -72.4 M -72.4 M -60.1 M -60.1 M -60.1 M -60.1 M -49.8 M -12.1 M -12.1 M -12.1 M -12.1 M -12.5 M -12.5 M -12.4 M -12.5 M -12.5 M -12.6 M -12.7 M -12.7 M -12.7 M -12.7 M -12.7 M -13 M -13 M -13 M -13 M

Total Assets

6.15 M 2.09 M 2.17 M 3.72 M 6.27 M 2.89 M 2.68 M 2.99 M 3.75 M 6.39 M 7.13 M 9.79 M 9.18 M 11.3 M 12.8 M 15.7 M 17.3 M 20.2 M 23.3 M 23.4 M 23.4 M 23.4 M 23.4 M 7.68 M 7.68 M 7.68 M 7.68 M 6.42 M 6.42 M 6.42 M 6.42 M 13.5 M 13.5 M 13.5 M 13.5 M 22.1 M 22.1 M 22.1 M 22.1 M 4.86 M 13.9 M 13.9 M 13.9 M 13.9 M 13.5 M 13.5 M 13.6 M 13.5 M 13.5 M 13.4 M 13.4 M 13.3 M 13.3 M 13.3 M 13.3 M 13.7 M 13.7 M 13.7 M 13.7 M

Cash and Cash Equivalents

5.29 M 980 K 949 K 2.37 M 4.93 M 1.42 M 949 K 1.1 M 1.84 M 4.3 M 4.86 M 7.36 M 6.67 M 8.61 M 6.7 M 12.9 M 15.9 M 18.5 M 21.5 M 21.4 M 21.4 M 21.4 M 21.4 M 5.58 M 5.58 M 5.58 M 5.58 M 5.36 M 5.36 M 5.36 M 5.36 M 12.7 M 12.7 M 12.7 M 12.7 M 21.4 M 21.4 M 21.4 M 21.4 M 3.56 M 13.8 M 13.8 M 13.8 M 3.18 M 13.5 M 13.5 M 13.6 M 13.3 M 13.5 M 13.4 M 13.3 M 13.3 M 13.3 M 13.3 M 13.3 M 12.7 M 12.7 M 12.7 M 12.7 M

Book Value

2.63 M -1.89 M -1.52 M 837 K 2.75 M -1.96 M -2.28 M -1.6 M -660 K 1.64 M 1.9 M 4.89 M 4.1 M 6.73 M 7.37 M 10.4 M 13.4 M 15.7 M 18.6 M 19.2 M 19.2 M 19.2 M 19.2 M 2.37 M 2.37 M 2.37 M 2.37 M 3.79 M 3.79 M 3.79 M 3.79 M 11.1 M 11.1 M 11.1 M 11.1 M 20.6 M 20.6 M 20.6 M 20.6 M -3.44 M 13.9 M 13.9 M 13.9 M 13.9 M 13.5 M 13.5 M 13.6 M 13.5 M 13.5 M 13.4 M 13.4 M 13.3 M 13.3 M 13.3 M 13.3 M 13 M 13 M 13 M 13 M

Total Shareholders Equity

2.63 M -1.89 M -1.52 M 837 K 2.75 M -1.96 M -2.28 M -1.6 M -660 K 1.64 M 1.9 M 4.89 M 4.1 M 6.73 K 7.37 M 10.4 M 13.4 M 15.7 M 18.6 M 19.2 M 19.2 M 19.2 M 19.2 M 2.37 M 2.37 M 2.37 M 2.37 M 3.79 M 3.79 M 3.79 M 3.79 M 11.1 M 11.1 M 11.1 M 11.1 M 20.6 M 20.6 M 20.6 M 20.6 M -3.44 M 13.9 M 13.9 M 13.9 M -43.1 M 13.5 M 13.5 M 13.6 M 13.3 M 13.5 M 13.4 M 13.4 M 13.3 M 13.3 M 13.3 M 13.3 M 13 M 13 M 13 M 13 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of BioCardia, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 6.4 - $ 63.3 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 21.41 - $ 1 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.9 -2.33 % $ 6.62 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 21.96 - $ 3.64 B usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.72 - $ 115 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 1.91 - $ 397 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.33 - $ 149 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 105.46 - $ 27.2 B germanyGermany
Heron Therapeutics Heron Therapeutics
HRTX
$ 1.19 - $ 198 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 8.36 - $ 75.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.08 - $ 436 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.26 - $ 2.96 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.48 - $ 152 M germanyGermany
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.44 - $ 383 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.41 - $ 235 M franceFrance
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Jaguar Health Jaguar Health
JAGX
$ 0.39 -0.18 % $ 910 K usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.91 - $ 4.79 M israelIsrael
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
$ 19.63 - $ 1.06 B britainBritain
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.28 - $ 260 M israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands